



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Datasheet for 009-001-T28S**SETD8 protein-GST fusion****Overview**

Description:	SETD8 recombinant protein-GST fusion protein - 009-001-T28S
Item No.:	009-001-T28S
Size:	20 µg
Origin:	Human
Expressed in:	Sf9 cells

Product Details

Background:	SETD8 or SET domain containing lysine methyltransferase 8 is a lysine methyltransferase that monomethylates p53 in human cell lines. The monomethylation by SETD8 suppresses p53-mediated transcriptional activation of highly responsive target genes, such as p21 (CDKN1A) and PUMA (BBC3) but it has little influence on weak p53 targets (1). Depletion of SET8 augmented the proapoptotic and checkpoint activation functions of p53, and SETD8 expression is downregulated during DNA damage. SETD8 is a Wnt signaling mediator and is recruited by LEF1/TCF4 to regulate the transcription of Wnt-activated genes, possibly through H4K20 monomethylation at the target gene promoters (2). SETD8 Protein is ideal for investigators involved in Signaling Proteins, Acetyl/Methyltransferase Proteins, Apoptosis/Autophagy, Cancer, Cell Cycle, and Neurobiology research.
Synonyms:	PR-Set7, SET07, SET8, N-lysine methyltransferase SETD8, H4-K20-HMTase SETD8, Histone-lysine N-methyltransferase SETD8, Lysine N-methyltransferase 5A, PR/SET domain-containing protein 07, PR-Set7, PR/SET07, SET domain-containing protein 8
Species of Origin:	Human
Expressed in:	Sf9 cells
Type:	Recombinant Protein

Target Details

Gene Name:	SETDB8
Purity/Specificity:	Recombinant full-length human SETD8 was expressed by baculovirus in Sf9 insect cells using an N-Terminal Glutathione-S-Transferase fusion protein. The purity was determined to be >85% by densitometry.

Relevant Links: • [NCBI - BC050346](#)

Application Details

Application Note:	SETD8 Protein is stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. SETD8 Protein is suitable for use in Western Blot. Expect a band approximately ~68kDa on specific lysates or tissues. Specific conditions for reactivity should be optimized by the end user.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
WB:	User Optimized

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	0.1 µg/µL
Buffer:	See application note.

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Expiration:	Expiration date is one (1) year from date of receipt.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

